Clinical Trials
4 trialsNCT02598661 2026-01-05
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation
Phase 2/3 Active not recruiting
NCT00310895 2015-12-24
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
Geron Corporation
Phase 1 Completed
NCT00594126 2015-12-24
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
Geron Corporation
Phase 1 Completed
NCT00718601 2015-12-24
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
Geron Corporation
Phase 1 Completed